Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28831197 | 0.86 | NPC1 (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28831109 | 0.83 | THRA (0.37) | ESR1ESR2LMNACYP1A2TSHR | |
| SCHEMBL28831256 | 0.80 | KMT2A (0.42) | LMNASMN1; SMN2MAPK1HPGDHTT | |
| SCHEMBL1454369 | 0.79 | CA1 (0.54) | CA1CA2ESR1CA12CA7 | |
| SCHEMBL29918654 | 0.79 | CA1 (0.46) | CA1CA2ESR1CA12CA7 | |
| SCHEMBL6756043 | 0.77 | ESR1 (0.45) | CA1CA2ESR1CA12CA7 | |
| SCHEMBL87450 | 0.77 | CA1 (0.83) | CA1CA2ESR1CA12CA7 | |
| SCHEMBL5164901 | 0.76 | ESR1 (0.77) | CA1CA2ESR1CA12CA7 | |
| SCHEMBL28831173 | 0.76 | NR1I2 (0.47) | CA1CA2SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL7746905 | 0.75 | CA1 (0.79) | CA1CA2ESR1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825233-B2 | SUBSTITUTED BONZOIC ACID DERIVATIVES, USEFUL FOR PREVENTING AND/OR TREATING TUMORS, ARTHRITIS, AND NON-MALIGNANT SKIN DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20020193421-A1 | Compounds having retinoid-like activity | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-19 | — | — | US | disclosed |
| WO-2002065984-A2 | COMPOUNDS HAVING RETINOID-LIKE ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193421-A1 | Compounds having retinoid-like activity | RARA, RARG, RARB | CA1 2330/4885CA2 3303/4885ESR1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.